Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility study of R-CHOP plus bevacizumab in patients with diffuse large B cell lymphoma
2006-003844-41Phase 2Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Cardiac and bevacizumab-specific toxicity. Started Feb 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2006-003844-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003844-41.